Brief: Reviva Announces Last Patient Evaluated In Pivotal Phase 3 Recover Trial For Brilaroxazine In Schizophrenia
25/09/2023 11:07
Sept 25 (Reuters) - Reviva Pharmaceuticals Holdings,
Inc. RVPH.O :
* REVIVA ANNOUNCES LAST PATIENT EVALUATED IN PIVOTAL PHASE 3
RECOVER TRIAL FOR BRILAROXAZINE IN SCHIZOPHRENIA
* REVIVA PHARMACEUTICALS HOLDINGS, INC. - TOPLINE DATA FROM
RECOVER ARE EXPECTED IN OCTOBER 2023
Source text for Eikon: ID:nGNX8Zx4XQ
Further company coverage: RVPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reviva Pharmaceuticals Holdings
See all newsReviva Pharmaceuticals Q1 net loss narrows on lower expenses
Brief: Reviva Pharmaceuticals Holdings Inc - To Be Delisted From Nasdaq Trading Suspended As Of May 14, 2026 - SEC Filing
Brief: Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights
Reviva Pharmaceuticals' 2025 net loss narrows on lower R&D spending
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture